麻疹、腮腺炎和德國麻疹疫苗市場－全球產業規模、佔有率、趨勢、機會和預測：按類型、目標受眾、分銷管道、地區和競爭格局分類，2021-2031年

全球麻疹、腮腺炎和德國德國麻疹(MMR) 疫苗市場預計將從 2025 年的 21.9 億美元大幅成長至 2031 年的 36.5 億美元，複合年成長率為 8.89%。

該市場的成長主要受幾個關鍵因素驅動。具體而言，這些因素包括政府機構嚴格執行國家免疫規劃、病毒爆發持續威脅需要強力的預防措施，以及世界衛生組織持續為脆弱地區的額外免疫活動提供資金支持，所有這些都確保了疫苗生產商穩定的供需關係。儘管有這些成長預測，但該市場仍面臨諸多障礙，主要是疫苗接種意願不足和物流方面的挑戰，這些都阻礙了全民覆蓋目標的實現。這些問題造成了巨大的免疫缺口，對公眾健康構成風險，並限制了市場的整體覆蓋範圍。例如，根據世界衛生組織（世衛組織）的報告，到2025年，全球麻疹疫苗首次接種率將僅為84%，這意味著超過2,000萬名兒童面臨感染該疾病的風險。這項短缺凸顯了相關人員在克服疫苗可及性問題、最大限度地提高市場滲透率方面所面臨的持續困難。

市場促進因素

全球麻疹和腮腺炎疫情的激增是推動市場擴張的主要因素，迫使公共衛生機構加快緊急採購並加強常規免疫接種方案。近期醫療衛生系統的中斷造成了嚴重的免疫缺口，導致感染率迅速回升。因此，亟需進行即時免疫接種宣傳活動，以防止疫情廣泛爆發。世界衛生組織（世衛組織）於2024年11月報告稱，2023年全球麻疹病例估計為1,030萬例，較去年同期成長20%。此次疫情的爆發直接導致各國政府為遏制疫情蔓延和重建群體免疫而加強對疫苗生產商的訂單量。此外，世界衛生組織提供的策略性資金和支持也是另一個關鍵驅動力，有效支撐了中低收入地區的市場需求，而這些地區持續高昂的疫苗價格仍然是一大障礙。全球疫苗免疫聯盟（Gavi）和聯合國兒童基金會（UNICEF）等合作夥伴組織正透過長期合約和對大規模免疫宣傳活動的津貼來彌補這一資金缺口，從而即使在當地經濟形勢不穩定的情況下，也能為生產商提供可預測的收入來源。根據全球疫苗免疫聯盟（Gavi）2024年5月發布的公告，該聯盟積極支持了多達1億名兒童的麻疹和德國麻疹後續及加強免疫接種宣傳活動，涵蓋了整個2024年。這表明，這種持續的組織支持如何顯著提升主要市場參與者的商業性業績，例如，默克公司（Merck & Co., Inc.）旗下ProQuad、MMR II和Varivax產品組合在2024會計年度的全球銷售額達到了24.85億美元。

市場挑戰

疫苗接種猶豫和持續存在的物流障礙是限制全球麻疹、腮腺炎和德國麻疹疫苗市場成長的主要因素，直接阻礙了市場擴張，因為這些因素導致生產者和醫療機構無法向所有目標人口提供疫苗。物流的複雜性，尤其是在偏遠和受衝突影響的地區，擾亂了這些生物製藥所必需的低溫運輸和分銷系統，導致庫存浪費和錯失接種機會。同時，對疫苗安全性的質疑正在顯著降低已開發國家和開發中國家的自願接種率，導致消費群大幅萎縮，而這與疫苗供應無關。這些障礙加劇了免疫力差異，削弱了全球根除目標，並使市場處於被動應對狀態，而非專注於實現穩定的全民免疫。在先前被認為安全的地區，疾病的再次爆發清楚地表明了疫苗在關鍵市場領域的滲透不足。根據世界衛生組織（世衛組織）的數據，到2024年，將有59個國家經歷大規模或造成社會混亂的麻疹疫情。這一數字幾乎是2021年的三倍，從統計數據來看，這表明儘管疫苗生產能力充足，但由於無法將疫苗供應到最終階段，以及終端用戶拒絕接受疫苗，正在從物理和社會層面限制市場的成長潛力。

市場趨勢

耐熱疫苗技術的進步正逐步重塑市場格局，有效應對了維持低溫運輸（尤其是在資源匱乏的環境中）所面臨的重大物流挑戰。諸如高密度微陣列貼片（HD-MAPs）等創新技術正在研發中，無需傳統冷藏即可維持疫苗穩定性，從而顯著減少庫存浪費，並簡化偏遠地區的配送流程。這項技術革新不僅增強了供應鏈的韌性，還提高了疫苗自我接種的可能性，從而使更多人群能夠在傳統臨床環境之外獲得疫苗。例如，Vaxxas公司於2025年8月籌集了約9,000萬澳元，用於將其專有的貼片平台商業化，該平台旨在最大限度地減少溫度控制需求。同時，隨著公共衛生部門努力彌補老年人因兒童疫苗接種不足和免疫力下降而造成的免疫缺口，針對成人和旅行者的接觸者追蹤計畫也日益受到重視。與標準的兒童疫苗接種計劃不同，這些措施尤其針對青少年和成年人，旨在預防大學和職場等人口密集環境中的疫情爆發，從而為疫苗生產商創造利潤豐厚的第二成長領域。這種向老年族群的策略性轉變對於維持群體免疫閾值至關重要。尤其是在疫情後免疫系統受到衝擊的情況下，美國疾病管制與預防中心（CDC）在2025年8月報告稱，美國13至17歲青少年接種兩劑或兩劑以上麻疹、腮腺炎、德國麻疹（MMR）疫苗的比例比前一年提高了1.3個百分點。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：麻疹、腮腺炎和德國麻疹疫苗的全球市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 按類型（單價、三價（MMR混合物）、四價）
  • 依目標群體分類（嬰兒（9個月至12歲）、成人）
  • 分銷管道（醫院/醫療機構、疫苗中心/公共衛生診所、小兒科、私人醫療機構）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美麻疹、腮腺炎和德國麻疹疫苗市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲麻疹、腮腺炎和德國麻疹疫苗市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區麻疹、腮腺炎和德國麻疹疫苗市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲麻疹、腮腺炎和德國麻疹疫苗市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲麻疹、腮腺炎和德國麻疹疫苗市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球麻疹、腮腺炎和德國麻疹疫苗市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Merck & Co., Inc.
• GlaxoSmithKline plc
• Pfizer Inc.
• Novartis AG
• Serum Institute of India Pvt. Ltd.
• Panacea Biotec Ltd.
• Takeda Pharmaceutical Company Limited
• Sinovac Biotech Ltd.
• Biological E. Limited
• Emergent BioSolutions Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Measles, Mumps, Rubella (MMR) Vaccine Market is projected to expand significantly, rising from USD 2.19 Billion in 2025 to USD 3.65 Billion by 2031, demonstrating an 8.89% Compound Annual Growth Rate. This market growth is propelled by several key factors: the strict implementation of national immunization schedules by government bodies, the ongoing threat of viral outbreaks demanding robust preventive measures, and consistent financial support from international health alliances for additional immunization activities in vulnerable regions, which ensures a steady demand and procurement volumes for vaccine manufacturers.\nDespite this projected growth, the market faces considerable obstacles, primarily vaccine hesitancy and logistical challenges that impede the achievement of universal coverage targets. These issues lead to critical immunity gaps, posing risks to public health and limiting the overall market reach. For instance, the World Health Organization reported that in 2025, global immunization coverage for the first dose of the measles vaccine was 84% for the preceding year, leaving more than 20 million children susceptible to the disease. This shortfall highlights the persistent difficulties stakeholders encounter in overcoming accessibility problems to maximize market penetration.

Market Driver

The increasing global incidence of measles and mumps outbreaks is a primary driver fueling market expansion, compelling public health agencies to accelerate emergency procurement and strengthen routine immunization protocols. Recent disruptions to healthcare systems have created significant immunity gaps, leading to a sharp resurgence in infection rates that necessitate immediate, large-scale vaccination campaigns to prevent widespread morbidity. The World Health Organization reported in November 2024 that global measles cases surged to an estimated 10.3 million in 2023, marking a 20% increase from the previous year, an epidemiological escalation that directly translates into higher volume orders for manufacturers as governments work to contain the spread and re-establish herd immunity.\nAdditionally, strategic funding and support from global health organizations serve as a crucial second driver, effectively underwriting market demand in low- and middle-income regions where vaccine affordability remains a significant barrier. Alliances such as Gavi and UNICEF bridge this financial divide by securing long-term contracts and subsidizing mass vaccination campaigns, thereby providing manufacturers with predictable revenue streams despite local economic volatility. According to a May 2024 announcement from Gavi, the Vaccine Alliance actively supported catch-up and follow-up campaigns targeting up to 100 million children with measles and rubella vaccines throughout 2024, demonstrating how this sustained institutional backing substantially boosts the commercial performance of key market players, exemplified by Merck & Co., Inc.'s global sales of US$ 2.485 billion for its combined ProQuad, M-M-R II, and Varivax portfolio in fiscal year 2024.

Market Challenge

Vaccine hesitancy and persistent logistical barriers represent a formidable constraint on the growth of the Global Measles, Mumps, and Rubella Vaccine Market, directly hindering its expansion by preventing manufacturers and healthcare providers from reaching the entire target population. Logistical complexities, particularly in remote or conflict-affected areas, disrupt the cold chain and delivery systems essential for these biological products, leading to inventory wastage and missed immunization opportunities. Concurrently, skepticism regarding vaccine safety significantly reduces voluntary uptake in both developed and developing nations, thereby effectively shrinking the consumer base regardless of supply availability.\nThese impediments consequently perpetuate immunity gaps that undermine global elimination goals, keeping the market in a reactive state rather than achieving the stability of universal coverage. This failure to adequately penetrate critical market segments is clearly evidenced by the resurgence of the disease in areas previously considered safe. The World Health Organization reported that in 2024, 59 countries experienced large or disruptive measles outbreaks, a figure nearly triple that of 2021, statistically indicating that despite manufacturing capabilities, the market's growth potential is physically and socially restricted by the inability to deliver doses to the final mile and the refusal of end-users to accept them.

Market Trends

The advancement in thermostable vaccine technologies is progressively shaping the market by effectively addressing critical logistical challenges associated with cold-chain maintenance, especially in low-resource settings. Innovations like high-density microarray patches (HD-MAPs) are being developed to maintain stability without traditional refrigeration, which significantly reduces inventory wastage and streamlines distribution to remote areas. This technological evolution not only enhances supply chain resilience but also supports potential for self-administration, thereby expanding vaccine accessibility beyond conventional clinical environments, as demonstrated by Vaxxas securing approximately A$90 million in August 2025 to commercialize its proprietary patch platform designed to minimize temperature control requirements.\nConcurrently, there is an increasing emphasis on adult and traveler catch-up programs, as public health authorities strive to close immunity gaps in older populations resulting from missed childhood doses or waning protection. Unlike standard pediatric schedules, these initiatives specifically target adolescents and adults to prevent outbreaks in high-density environments such as universities and workplaces, effectively cultivating a secondary growth segment for manufacturers. This strategic shift toward older demographics is crucial for sustaining herd immunity thresholds, particularly in the wake of post-pandemic immunization disruptions, with the Centers for Disease Control and Prevention reporting in August 2025 that coverage with at least two doses of the MMR vaccine increased by 1.3 percentage points among adolescents aged 13-17 years in the U.S. compared to the previous year.

Key Market Players

• Merck & Co., Inc.
• GlaxoSmithKline plc
• Pfizer Inc.
• Novartis AG
• Serum Institute of India Pvt. Ltd.
• Panacea Biotec Ltd.
• Takeda Pharmaceutical Company Limited
• Sinovac Biotech Ltd.
• Biological E. Limited
• Emergent BioSolutions Inc.

Report Scope

In this report, the Global Measles, Mumps, Rubella Vaccine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Measles, Mumps, Rubella Vaccine Market, By Type

• Monovalent
• Trivalent (combined MMR)
• Tetravalent

Measles, Mumps, Rubella Vaccine Market, By Targeted Population

• Infants and children (9 months to 12)
• Adults

Measles, Mumps, Rubella Vaccine Market, By Distribution Channel

• Hospitals and Healthcare Institutions
• Vaccine Centers and Public Health Clinics
• Pediatric
• Private Healthcare Clinics

Measles, Mumps, Rubella Vaccine Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Measles, Mumps, Rubella Vaccine Market.

Available Customizations:

Global Measles, Mumps, Rubella Vaccine Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Measles, Mumps, Rubella Vaccine Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Monovalent, Trivalent (combined MMR), Tetravalent)
  • 5.2.2. By Targeted Population (Infants and children (9 months to 12), Adults)
  • 5.2.3. By Distribution Channel (Hospitals and Healthcare Institutions, Vaccine Centers and Public Health Clinics, Pediatric, Private Healthcare Clinics)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Measles, Mumps, Rubella Vaccine Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Targeted Population
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Measles, Mumps, Rubella Vaccine Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Targeted Population
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada Measles, Mumps, Rubella Vaccine Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Targeted Population
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico Measles, Mumps, Rubella Vaccine Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Targeted Population
      • 6.3.3.2.3. By Distribution Channel

7. Europe Measles, Mumps, Rubella Vaccine Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Targeted Population
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Measles, Mumps, Rubella Vaccine Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Targeted Population
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. France Measles, Mumps, Rubella Vaccine Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Targeted Population
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom Measles, Mumps, Rubella Vaccine Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Targeted Population
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Measles, Mumps, Rubella Vaccine Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Targeted Population
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Measles, Mumps, Rubella Vaccine Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Targeted Population
      • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Measles, Mumps, Rubella Vaccine Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Targeted Population
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Measles, Mumps, Rubella Vaccine Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Targeted Population
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Measles, Mumps, Rubella Vaccine Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Targeted Population
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Japan Measles, Mumps, Rubella Vaccine Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Targeted Population
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. South Korea Measles, Mumps, Rubella Vaccine Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Targeted Population
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Measles, Mumps, Rubella Vaccine Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Targeted Population
      • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Measles, Mumps, Rubella Vaccine Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Targeted Population
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Measles, Mumps, Rubella Vaccine Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Targeted Population
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. UAE Measles, Mumps, Rubella Vaccine Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Targeted Population
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. South Africa Measles, Mumps, Rubella Vaccine Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Targeted Population
      • 9.3.3.2.3. By Distribution Channel

10. South America Measles, Mumps, Rubella Vaccine Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Targeted Population
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Measles, Mumps, Rubella Vaccine Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Targeted Population
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Colombia Measles, Mumps, Rubella Vaccine Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Targeted Population
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. Argentina Measles, Mumps, Rubella Vaccine Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Targeted Population
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Measles, Mumps, Rubella Vaccine Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Merck & Co., Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. GlaxoSmithKline plc
• 15.3. Pfizer Inc.
• 15.4. Novartis AG
• 15.5. Serum Institute of India Pvt. Ltd.
• 15.6. Panacea Biotec Ltd.
• 15.7. Takeda Pharmaceutical Company Limited
• 15.8. Sinovac Biotech Ltd.
• 15.9. Biological E. Limited
• 15.10. Emergent BioSolutions Inc.

16. Strategic Recommendations

17. About Us & Disclaimer